Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
February 29 2024 - 10:19AM
Business Wire
- The Unseen Journey brings to life the
often-misunderstood impact of common myeloproliferative neoplasm
(MPN) symptoms through AI-generated images developed from the words
and experiences of real patients
Incyte (Nasdaq: INCY) today announced the launch of The Unseen
Journey, a program that brings to life the hidden emotional and
physical toll of myeloproliferative neoplasms (MPNs), a group of
rare, chronic and progressive blood cancers. Through the use of
generative artificial intelligence (AI), the stories and
experiences of MPN patients were transformed into unique images to
help them show their health care team and their loved ones the
significant impact of their MPN symptoms.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240229692531/en/
(Photo: Business Wire)
The Unseen Journey highlights the stories of people living with
MPNs who were asked to describe their symptoms and how they impact
their lives in their own words. As each patient described their
symptoms and experiences, generative AI tools transformed their
words into images that visually depict the patient’s most
burdensome symptoms. The resulting images provide a vivid look at
the reality of living with an MPN.
“MPN symptoms can be difficult to recognize and describe and
every patient’s experience is different, which can sometimes create
a challenge for patients, their loved ones and their health care
teams to understand the impact of the condition to daily life,”
said Ann Brazeau, CEO and Founder, MPN Advocacy and Education
International. “These AI-generated images paint a vivid picture of
what it is like to live with an MPN, and I hope they will help
create a new level of awareness and empathy for those with these
conditions.”
Polycythemia vera (PV), myelofibrosis (MF) and essential
thrombocythemia (ET) are the most common MPNs. MPNs are progressive
diseases that can worsen over time, and changes in symptoms, which
can also be a sign of disease progression, can be subtle and hard
to assess1. It is important for MPN patients to track their
symptoms on a regular basis to help inform conversations with their
health care provider.
“I regularly struggle with my MPN symptoms, including fatigue,
brain fog and headaches, but because I don’t look sick on the
outside, people in my life have trouble truly understanding what I
am going through,” said Chelsea, who has been living with PV since
2018. “The AI-generated images created of my symptoms capture how I
often feel in a way I could never describe to my friends and
family. I hope my images and story resonate with other people
living with MPNs and inspire them to proactively share what they
are going through with the people in their lives.”
The Unseen Journey website showcases stories of people living
with MPNs as shown by AI-generated images and behind-the-scenes
videos detailing how the imagery was created. It also includes
tools and resources to support people living with MPNs to
proactively identify, track and discuss their symptoms or any
changes in their health with their health care team.
“There is a need to raise greater awareness of MPN symptoms and
their significant impact on patients, and the use of AI technology
allows us to illustrate the patient experience in a new and
striking way,” said Barry Flannelly, General Manager, Incyte North
America. “At Incyte, we are committed to serving the needs of those
living with MPNs and other difficult to treat conditions and look
forward to supporting more patients in the future.”
About MPNs
Myeloproliferative neoplasms (MPNs) are a group of rare, chronic
blood cancers in which a person’s bone marrow does not function
properly. MPNs are progressive diseases, meaning they can worsen
over time. The three most common MPNs include polycythemia vera
(PV), myelofibrosis (MF), and essential thrombocythemia (ET). MPNs
can occur at any age, but are more common in older adults.
About Incyte
A global biopharmaceutical company on a mission to Solve On.,
Incyte follows the science to find solutions for patients with
unmet medical needs. Through the discovery, development and
commercialization of proprietary therapeutics, Incyte has
established a portfolio of first-in-class medicines for patients
and a strong pipeline of products in Oncology and Inflammation
& Autoimmunity. Headquartered in Wilmington, Delaware, Incyte
has operations in North America, Europe and Asia. For additional
information on Incyte, please visit Incyte.com or follow us on
social media: LinkedIn, X, Instagram, Facebook, YouTube.
Forward-Looking Statements
Except for the historical information set forth herein, the
matters set forth in this press release, including statements
regarding the Company’s research in and approach to rare blood
cancers and their treatment contain predictions, estimates, and
other forward-looking statements.
These forward-looking statements are based on the Company’s
current expectations and subject to risks and uncertainties that
may cause actual results to differ materially, including
unanticipated developments in and risks related to: unanticipated
delays; further research and development and the results of
clinical trials possibly being unsuccessful or insufficient to meet
applicable regulatory standards or warrant continued development;
the ability to enroll sufficient numbers of subjects in clinical
trials and the ability to enroll subjects in accordance with
planned schedules; determinations made by the FDA or other
regulatory authorities; the Company’s dependence on its
relationships with its collaboration partners; the efficacy or
safety of the Company’s products and the products of the Company’s
collaboration partners; the acceptance of the Company’s products
and the products of the Company’s collaboration partners in the
marketplace; market competition; sales, marketing, manufacturing
and distribution requirements; and other risks detailed from time
to time in the Company’s reports filed with the Securities and
Exchange Commission, including its annual report on Form 10-K for
the year ended December 31, 2023. The Company disclaims any intent
or obligation to update these forward-looking statements.
____________________________________________ 1Leukemia &
Lymphoma Society. Myeloproliferative Neoplasms.
www.lls.org/sites/default/files/National/USA/Pdf/Publications/MPNs_booklet_12_17_FINAL.pdf
Accessed January 2024.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229692531/en/
Media Jenifer Antonacci +1 302 498 7036
jantonacci@incyte.com Kristen Griffiths, +1 302 498 7012
kgriffiths@incyte.com Investors Greg Shertzer +1 302 274
4779 gshertzer@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2024 to Jul 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2023 to Jul 2024